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Epstein–Barr virus (EBV) and human immunodeficiency virus type 1 (HIV-1), as well as human T-cell leukemia-lymphoma
virus type I (HTLV-I), may interact in the pathogenesis of human retroviral infections. The placental syncytiotrophoblast
layer represents a barrier protecting the fetal compartment from exposure to retroviruses. We studied the interactions of
EBV with HIV-1 and HTLV-I in human term syncytiotrophoblast cells to investigate the significance of double infections in
transplacental transmission of human retroviruses. We found that syncytiotrophoblast cells could be productively infected
with EBV. Dual infection of the cells with EBV and HTLV-I resulted in full replication cycle of otherwise latent HTLV-I. In
contrast, the restricted permissiveness of syncytiotrophoblasts for HIV-1 was not influenced by coinfection of the cells with
EBV. Infection of syncytiotrophoblast cells with EBV, but not HTLV-I, induced interleukin-2 and interleukin-6 secretion, and
augmented secretion occurred on coinfection with both viruses. Coinfection of syncytiotrophoblast cells with EBV and HTLV-
I induced tumor necrosis factor-b and transforming growth factor-b1 secretion, but infection with either virus alone did not
lead to secretion of these cytokines. Permissive replication cycle of HTLV-I was induced by the EBV immediate-early gene
product Zta. Pseudotype formation between EBV and HTLV-I in coinfected syncytiotrophoblast cells was not found. Our
data suggest that activation of HTLV-I gene expression by EBV in coinfected syncytiotrophoblast cells may be a mechanism
for transplacental transmission of HTLV-I. q 1997 Academic Press
INTRODUCTION Despite the fact that HIV-1 can enter ST cells, the tropho-
blast is assumed to restrict the rate of virus transmission,
The susceptibility of the syncytiotrophoblast to infec-
because trophoblast cells exhibit restricted permis-
tion by human retroviruses is of major interest.
siveness for HIV-1 (Zachar et al., 1991). Similarly, human
Mother-to-child transmission is clearly an important
trophoblastic cells may become persistently but essen-
mode of spread for human immunodeficiency virus type
tially nonproductively infected with HTLV-I (Liu et al.,
1 (HIV-1) (Rubinstein, 1986). Although this may occur by
1995). These findings suggest that multiple cofactors are
several routes, including intrapartum transmission
likely to be involved in the transplacental transmission
(Ziegler et al., 1985) and breast feeding (Thiry et al., 1985),
of these viruses.
it is currently believed that intrauterine transplacental One possible mechanism for induction and stimulation
infection of the fetus in utero is the most important mech- of replication of human retroviruses is coinfection with
anism of vertical transmission (Mano and Chermann, human herpesviruses. We have reported that previous
1991; Katz and Wilfert, 1989). or simultaneous infection of ST cells with human cyto-
Human T cell leukemia-lymphoma virus type I (HTLV- megalovirus (HCMV) results in marked upregulation of
I) is known to be vertically transmitted from mothers to HIV-1 replication (To´th et al., 1995a), and dual infection of
children (Nakano et al., 1986). The main route of mother- ST cells with HCMV and HTLV-I can induce simultaneous
to-child transmission of HTLV-I is thought to be by breast replication of both viruses (To´th et al., 1995b). Among
feeding (Kinoshita et al., 1987). However, several previ- human herpesviruses, Epstein–Barr virus (EBV) may also
ous reports have suggested the possibility of intrauterine receive particular attention as a potential cofactor in
HTLV-I infection (Saito et al., 1990; Satow et al., 1991). transplacental transmission of human retroviruses. EBV
The placental syncytiotrophoblast (ST) is in intimate is a human lymphotropic virus whose main target cells
contact with maternal tissues and body fluids and it is have traditionally been described as B cells (Miller, 1990)
the first barrier to viral transmission from mother to fetus. and epithelial cells (Lemon et al., 1977). The reactivation
of EBV infection in HIV-positive subjects is significantly
higher than that in the general community (Sculley et al.,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (45)-86-195415. 1990). Some biologic assays involving EBV have demon-
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strated an increased production of HIV after coinfection formation was revealed by desmoplakin staining and
measuring the release of human chorionic gonadotropin(Salahuddin et al., 1987; Henderson et al., 1991). Yet, in
other studies with cotransfected cells, EBV immediate- from trophoblasts. The whole procedure has been de-
scribed previously in detail (To´th et al., 1995a). We usedearly (IE) gene products were found to transactivate the
long terminal repeat (LTR) of HIV-1 (Quinlivan et al., 1990; 5-day-old ST cultures consisting of large multinucleated
cells in all experiments. Cell cultures used throughoutMallon et al., 1990; Hammarskjo¨ld and Simurda, 1992;
Scala et al., 1993). Several data suggest that EBV and our studies were free of mycoplasma.
HTLV-I may also interact in various target cells of dually
Virusesinfected persons (Yamamoto et al., 1982; Tokunaga et
al., 1993).
The IIIB strain of HIV-1 was grown in H9 cells. The
We report here in vitro evidence for direct infection by
HTLV-I was prepared from the supernatants of the HTLV-
EBV and replication of the virus in cultured human ST
I producer MT-2 cell line. Supernatants were clarified for
cells. We find that dual infection of ST cells with EBV
10 min at 1000 g at 47, filtered through 0.45-mm pore size
and HTLV-I can convert HTLV-I infection from an abortive
filters, and concentrated to 30-fold by ultrafiltration in a
to a permissive one. In contrast, no interactions occur
sterile Centriprep-30 concentrator (Amicon, Inc., Beverly,
between EBV and HIV-1 in coinfected cells. Our data
MA). The HIV-1 and HTLV-I preparations were treated
suggest that EBV may play a critical role in the transpla-
with DNase (80 U/ml) (Promega, Madison, WI) for 1 hr
cental transmission of HTLV-I.
at 377 before their use for infection.
EBV strains were prepared from B95-8, Akata, Jijoye,
MATERIALS AND METHODS P3HR-1, and AG 876 cell cultures which, after reaching
5 1 105 cells per milliliter, had been treated for 4 daysCell lines
with 20 ng 21-O-tetradecanoylphorbol-13-acetate (TPA)
EBV-negative Burkitt’s lymphoma cell line Ramos (Sigma Chemical Co., St. Louis, MO) per milliliter (Zur
(Klein et al., 1975), EBV-positive B cell lines B95-8 (Miller Hausen et al., 1978). Supernatants, harvested from cul-
et al., 1972), Akata (Takada, 1984), Jijoye (Pulvertaft, tures, were centrifuged at 1000 g to sediment cells and
1965), P3HR-1 (Hinuma et al., 1967), AG 876 (Pizzo et al., passed through a 0.45-mm pore size filter. Viruses were
1978), Raji (Pulvertaft, 1964), and HTLV-I producer MT-2 then pelleted at 113,000 g for 1 hr at 47, followed by
cell line (Miyoshi et al., 1981) were grown in RPMI 1640 decanting, gentle washing of the pellet, and resus-
medium containing 10% fetal calf serum (FCS), 2 mM pending in 1 ml complete medium for each 30 ml of
glutamine, plus penicillin (100 U/ml) and streptomycin supernatant.
(100 mg/ml). The human osteogenic sarcoma (HOS) cell Concentrated viruses were stored at 0807. All virus
line (McAllister et al., 1971) was cultured in Dulbecco stocks were found to be mycoplasma free.
modified Eagle’s medium supplemented with 10% FCS
and antibiotics. All cell lines were free of mycoplasma Virus titrations
contamination at the time of the experiments.
The amount of HIV-1 in virus stocks and supernatants
of virus-infected cultures was determined by reverseIsolation, culture, and differentiation of
transcriptase (Hoffman et al., 1985) and CEM-SS syncy-cytotrophoblast cells
tium-forming (Nara et al., 1987) assays.
The HTLV-I samples were quantitated by measuringPure populations of term placental trophoblast cells
were separated according to a standard procedure the reverse transcriptase activity of the virus pellet (Rho
et al., 1981) and infectivity of the virus in HOS cells (Clap-(Douglas and King, 1989). Briefly, a cell preparation highly
enriched for cytotrophoblasts was obtained using a dis- ham et al., 1983).
The transforming titers of B95-8, Akata, Jijoye, and AGcontinuous Percoll gradient and the remaining contami-
nating cells were then removed using immunomagnetic 876 strains of EBV were measured on human cord blood
mononuclear cells with a microwell limiting dilutionmicrospheres. The purity of the trophoblast population
was tested by indirect immunofluorescence using mono- assay (Henderson et al., 1977). Each sample was as-
sayed in quadruplicate. A 100-ml volume of virus dilutionsclonal mouse IgG antibodies to cytokeratin, vimentin, as
well as to CD3, CD14, CD31, and CD68 cell surface mark- and 1 1 105 cells in 50 ml medium were added to each
well. Half the medium in each well was removed weekly,ers. The cells isolated by this procedure were cytokeratin
positive and considered to be pure cytotrophoblasts. Cell and fresh complete medium was replaced. The plates
were examined for transformed cells at various intervals,viability was determined by trypan blue dye exclusion.
Isolated trophoblast populations were viable in excess and final results were scored at 8 weeks. Virus titers
were given in transforming units per milliliter.of 95%. For in vitro differentiation of trophoblast cells,
keratinocyte growth medium (Clonetics Corp., San Diego, Nontransforming P3HR-1 EBV was titrated by its ability
to induce early antigen (EA) in the EBV genome-positiveCA) supplemented with 15% FCS was used. Syncytium
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nonproducing Raji cell line (Henle et al., 1970). To deter- Type Culture Collection. Murine MAb to HIV-1 Tat protein
was from American BioTechnologies (Cambridge, MA),mine the EA-inducing capacity of different virus samples,
5 1 105 viable Raji cells were sedimented by low-speed and mouse MAb to HIV-1 p24 antigen was from Dako.
The rabbit polyclonal antiserum against the full-lengthcentrifugation, dispersed in 500 ml of different serial dilu-
tions of the samples, and incubated at 377 for 1 hr. New Tax protein of HTLV-I (Jeang et al., 1990) was obtained
through the AIDS Research and Reference Reagent Pro-medium was added to bring the cell concentration to 3
1 105 cell/ml and the cultures were incubated for 3 days. gram (Division of AIDS Program, NIAID, Rockville, MD).
The goat polyclonal antiserum to HTLV-I p24 (Kalyarana-Subsequently, the cells were harvested and the fre-
quency of EA-positive cells was assessed on stained man et al., 1981) was a generous gift from R. C. Gallo
(National Cancer Institute, Bethesda, MD). Mouse MAbssmears, in parallel with untreated controls. P3HR-1 titers
were expressed in EA-inducing U/ml. OKB-7 and HB-5a specific for human CR2 (CD21) were
obtained from Ortho Diagnostics (Raritan, NJ) and Coulter
Coinfection procedure Immunology (Hialeah, FL), respectively. Neutralizing
MAbs to human IL-2, IL-6, and TNF-b were purchasedThe interaction between EBV and human retroviruses
from Boehringer GmbH (Mannheim, Germany). Thewas examined in timed experiments in which either ST
chicken anti-TGF-b1 polyclonal neutralizing antibodiescells were infected simultaneously with both viruses or
were obtained from R & D Systems.one virus was added to the cells earlier than the other.
Rabbit anti-mouse Ig conjugated to FITC, swine anti-Single virus controls received the same quantity of EBV,
rabbit Ig conjugated to FITC, rabbit anti-goat Ig conju-HIV-1, or HTLV-I. Five-day-old ST cultures were infected
gated to FITC, and rabbit anti-mouse Ig conjugated toin 25-cm2 flasks with HIV-1 or HTLV-I at a viral multiplicity
TRITC were purchased from Dako.of infection (m.o.i.) of 1.0 cpm RT/cell. Infections with
transforming EBV strains and P3HR-1 strain of EBV were
Immunofluorescence assayperformed at a m.o.i. of 1.0 transforming U and 1.0 EA-
inducing U per cell, respectively. The m.o.i. was calcu- The cell cultures for immunofluorescent staining were
lated according to the number of cytotrophoblast cells made in chamber slides (Nunc, Copenhagen, Denmark).
seeded for syncytium formation. The cells were incu- Single- and dual-label indirect immunofluorescence
bated with virus for 2 hr at 377 and then washed five staining was performed as described (To´th et al., 1995a).
times with serum-free medium. The final wash was taken EBV antigens were detected with mouse MAbs to Zta,
for detection of residual virus. Then completed medium EBNA-2, EA-D, and VCA, which were diluted at 1:20, 1:30,
was added to the cells. 1:50, and 1:40, respectively. A 1:40 dilution of the mouse
MAb to HIV-1 p24 and a 1:1000 dilution of the mouse
Assay for cytokine determination MAb to HIV-1 Tat protein were used for the assay. The
rabbit immune serum to HTLV-I Tax was diluted atSupernatants of virus-infected and uninfected control
1:1000, and the goat immune serum to HTLV-I p24 wascultures were assayed for interferon-a (IFN-a), IFN-b,
used at a 1:40 dilution. The FITC-conjugated rabbit anti-interleukin-1a (IL-1a), IL-1b, IL-2, IL-6, tumor necrosis
mouse Ig, swine anti-rabbit Ig, and rabbit anti-goat Igfactor-a (TNF-a), TNF-b, transforming growth factor-b
were diluted at 1:20.(TGF-b), and granulocyte-macrophage colony-stimulat-
Simultaneous detection of HTLV-I p24 and EBV VCAing factor (GM-CSF) activities. Commercial ELISA kits for
in dually infected ST cells was carried out by doubleIFN-a and IFN-b were from Serotec (Kidlington, Oxford,
indirect cytoplasmic immunofluorescence (IFA). TheUK). ELISA kits for IL-6, TNF-a, and GM-CSF were prod-
TRITC-conjugated rabbit anti-mouse Ig was used at aucts of Innogenetics NV, Zwijnaarde, Belgium). ELISA
1:20 dilution. As specific controls, uninfected cells andkits for IL-1a, IL-1b, IL-2, TNF-b, and TGF-b were pur-
normal sera were included in the experiments.chased form R & D Systems (Minneapolis, MN). Quantita-
tion of various TGF-bs was performed as previously de-
Western immunoblotting analysisscribed (To´th et al., 1995b).
Proteins from cell samples were separated by poly-
Immune sera and conjugates
acrylamide gel electrophoresis and blotted onto nitrocel-
lulose as previously described by Wong and LevineMouse monoclonal antibodies (MAbs) to IE Zta and
EBNA-2 antigens of EBV were purchased from Dako (Co- (1989). Excess protein binding sites on the transfer mem-
brane were blocked in a modified Denhardt’s solutionpenhagen, Denmark). Mouse MAbs recognizing the dif-
fuse component of the early antigen (EA-D) and the viral (Cohen et al., 1984) twice for 15 min at room temperature.
Polypeptides of permissive cycle were detected in paral-capsid antigen (VCA) of EBV were from Chemicon Inter-
national, Inc. (Temecula, CA). The hybridoma (HB 167) lel on one Western blot by serial incubation of anti-Zta
and anti-EA-D MAbs and staining in different colorsproducing neutralizing MAb (72A1) to gp350/220 of EBV
(Hoffman et al., 1980) was obtained from the American (Marschall et al., 1989). MAbs were diluted in modified
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Denhardt’s solution and added to the transfer membrane Covalent attachment of antibodies to the outer
surface of liposomesfor 12 hr at room temperature. For this purpose MAbs to
Zta and EA-D were diluted 1:200 and 1:500, respectively.
MAbs to Zta, EA-D, and VCA of EBV were chemicallyAfter antibody incubation, the membrane was washed
modified to increase cellular penetration by covalent at-three times in the solution. Then the filter was incubated
tachment of antibodies to the external surface of lipo-for 2 hr at room temperature with either peroxidase
somes. The passage of chemically modified antibodies(POD)- or alkaline phosphatase (AP)-conjugated rabbit
through the cytoplasm to the nucleus was evaluated byanti-mouse immunoglobulin in a dilution of 1:1,000
detection of radioactively labeled antibodies in the vari-(Dako). After washing, color reactions were achieved
ous subcellular fractions of syncytiotrophoblasts. Beforewith different substrates. Brown POD substrate was 0.5
linking to liposomes, antibodies were labeled with 125Img of 3,3*-diaminobenzidine per milliliter, 0.01% H2O2 ,
by the chloramine-T method (Greenwood et al., 1963). STand 50 mM Tris (pH 7.5). Red AP substrate was 1 mg
cells cultured in chamber slides were incubated withof Fast Red (Bio-Rad Laboratories, Hercules, CA) per
chemically modified, radioactively labeled antibodies atmilliliter, 0.5 mg of 4-chloro-1-naphtol per milliliter, 50
various concentrations. At different time intervals, themM Tris (pH 9.5), and 0.5 mM MgCl2 . The molecular
medium was removed, and subcellular fractions weresizes of detected polypeptides were determined by com-
separated as described by New et al. (1990). Then sam-parison with a protein standard (Sigma).
ples of each fraction were counted for radioactivity. The
peak value of radioactivity in the nuclear fraction couldPurification of gp350/220 of EBV
be detected as early as 2 hr after exposure. The rates
of relative specific activity in this cellular compartmentPurification of gp350/220 was based on the method of
were 24.2, 26.4, and 23.6% for liposome-coupled anti-Zta,Thorley-Lawson and Poodry (1982). Briefly, tetradeca-
anti-EA-D, and anti-VCA MAbs, respectively. These datanoylphorbol-13-acetate-treated P3HR-1 cells were lysed
indicated the traffic of antibodies to the nucleus. A de-by nitrogen cavitation, and crude plasma membranes
tailed description of the procedure has been given else-were prepared by differential centrifugation (Thorley-
where (To´th et al., 1995a).Lawson and Edson, 1979). The plasma membranes were
solubilized by the addition of sodium deoxycholate at a
protein/deoxycholate ratio of 1:3 for 30 min at 47. After Transfection of BZLF1 expression vector into
this time, the solution was centrifuged at 100,000 g for syncytiotrophoblast cells
30 min. Glycoproteins were purified from the clarified
supernatant by affinity chromatography on a 10-ml Seph- The pCMV-BZLF1 plasmid containing the BZLF1 gene
under the control of the human cytomegalovirus promoterarose column (Pharmacia, Uppsala, Sweden) of Ricinus
communis agglutinin II (Sigma Chemical Co., St. Louis, as previously described (Hammerschmidt and Sugden,
1988) was a gift of W. Hammerschmidt (Forschungszen-MO). The column was preequilibrated with lectin buffer
containing 0.2% Triton X-100, 0.1 mM MnCl2 , 0.14 M trum fu¨r Umwelt und Gesundheit, GmbH, Mu¨nchen, Ger-
many). Transfection of pCMV-BZLF1 plasmid into ST cellsNaCl, 0.25 mM dithiothreitol, and 10 mM Tris, pH 7.8, and
washed extensively with lectin buffer after application of was accomplished using the lipofectin procedure de-
scribed previously (Felgner et al., 1987). Three days be-the sample. The absorbed glycoproteins were eluted with
10% galactose in lectin buffer. The material which eluted fore transfection, trophoblast cells were seeded in 10-
cm2 flasks at a density of 5 1 105 cells/cm2. The STwas then passed over a 5-ml column of Sepharose 4-B,
normal mouse immunoglobulin coupled to Sepharose 4- cultures were transfected in triplicate with the BZLF1
expression construct pCMV-BZLF1. Before transfection,B, and finally, 72A1 MAb coupled to Sepharose 4-B. The
effluent was monitored at 280 nm in spectrophotometer. ST cells were fed with fresh keratinocyte growth medium.
After 4 hr, cells were washed twice with serum-free me-Specifically bound material was eluted with 0.2% deoxy-
cholate–50 mM diethylamine (pH 10.5). The fractions dium before the addition of 1 ml medium containing 30
ml lipofectin reagent (Gibco BRL, Paisley, UK) and 5 mgcontaining protein were pooled and dialyzed against
PBS. The isolated material was virtually pure gp350/220 of plasmid DNA. The cells were incubated with DNA/
liposome complex for 4 hr at 377 and then 1 ml completeas checked by SDS–polyacrylamide gel electrophoresis.
medium was added to the cultures. After an additional
incubation for 20 hr at 377, the medium was removed,Isolation of specific antibodies from the chicken
the cells were washed once with serum-free medium,polyclonal antiserum to TGF-b1
and fresh medium containing 15% FCS was added.
The expression of Zta protein in transfected cells wasThe preparation of the antigen in an insoluble form and
the dissociation of specific antibodies from the antigen- checked by indirect cytoplasmic IFA. The presence of Zta
could be detected as long as 7 days after transfection,cellulose has been described previously (To´th et al.,
1995a). Human TGF-b1 was purchased from Sigma. showing maximum levels 48–72 hr posttransfection.
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Polymerase chain reactions infected cells lacked evidence of EBV infection by immu-
nofluorescence.
For detection of EBV DNA in the cells, a protocol de- To confirm the results obtained by immunofluores-
scribed by Saito et al. (1989) was used. The two Bam cence staining, protein samples from EBV-infected ST
W primers were 5*-CCAGAGGTAAGTGGACTT-3* and 5*- cells, and appropriate controls were analyzed for the
GACCGGTGCCTTCTTAGG-3* and the oligonucleotide expression of Zta and EA-D by Western blotting. Results
probe was 5*-TTCTGCTAAGCCCAAC-3*. Amplification of of experiment performed with the AG 876 strain of EBV
the DNA was carried out by means of a thermocycler are shown in Fig. 2. None of the MAbs against permissive
(Perkin–Elmer–Cetus, Norwalk, CT) with denaturation at cycle antigens reacted with the EBV genome-negative
937, annealing at 567, and extension at 727 for 40 cycles. Ramos cells or with the EBV genome-positive, latently
Amplification products were subjected to electrophoresis infected Raji cell line. Both of them reacted, however,
in 1% agarose gel, transferred onto a Hybond NTC mem- with the TPA-activated AG 876 cell line and AG 876 virus-
brane (Amersham, Little Chalfont, UK), and hybridized infected ST cells. Similar results were also obtained with
with 32P-end-labeled probe at 427 for 1 hr. The filter was ST cells infected with other EBV strains (data not shown).
washed twice with 61 SSPE (1 M NaCl, 60 mM NaH2PO4 , Progeny virions produced by EBV-infected ST cells
6 mM EDTA, pH 7.4), 0.1% SDS at room temperature, were detected by their ability to transform cord blood B-
followed by wash for 10 min at 557 and autoradiography lymphocytes or to induce EA in the Raji cell line (Fig. 3).
at 0707. There were no significant differences between individual
Detection of HTLV-I proviral DNA by PCR was carried virus strains in the efficiency of replication. Release of
out as previously described (To´th et al., 1995b). infectious EBV by ST cells could be detected first on Day
6 postinfection. The virus yield reached a peak value on
RESULTS Day 12, and sharply decreased thereafter. No infectious
virus was found in supernatants harvested after Day 18Virus replication in ST cells infected with HIV-1,
postinfection. Maximal release of transforming EBVHTLV-I, or EBV alone
strains by infected ST cultures varied from 1.0 to 4.8 1
103 transforming units per milliliter of supernatant fluid.As we previously reported (To´th et al., 1995a, 1995b),
HIV-1-infected cells expressed Tat protein and produced The highest level of P3HR-1 virus production was 3.7 1
103 EA inducing units per milliliter. Interestingly, EBV-low amounts of infectious virus, whereas neither Tax
expression nor virus release was observed in HTLV-I- producing ST cultures survived after 18 days.
infected cell cultures (data not shown).
We examined EBV-infected ST cultures for evidence Specificity of EBV binding to ST cells
of entry into virus productive cycle using MAbs against
Zta, EA-D, and VCA. Zta-specific fluorescence was de- To determine which receptors were responsible for
binding of EBV to ST cells, we attempted to block EBVtected as early as at 24 hr after infection and persisted
as long as 12 days in the culture. Granular staining in infection by using purified gp350/220 and MAbs known
to block the function of CR2 or binding of gp350/220 tothe nucleus and faint perinuclear fluorescence were
noted (Fig. 1A). Up to 70% of nuclei in EBV-infected cul- CR2. ST cells were incubated with anti-CR2 MAbs or
purified gp350/220 for 1 hr at 47 and washed three timesture became Zta-positive within 3 days of infection. The
diffuse component of the early antigen was detectable with PBS before EBV infection. In other blocking experi-
ments concentrated virus was incubated with MAb 72A1first at 36 hr postinfection and reached a maximum level
on Day 4. The percentage of cells expressing EA-D was for 1 hr at 47 prior to addition to the cells. Results of
blocking experiments performed with AG 876 strain ofabove 70% in each of the infection. The anti-EA-D MAb
was seen to react primarily with the nuclei of infected EBV are shown in Fig. 4. The rate of inhibition of EBV
infectivity was evaluated by the decrease in the numbercells but some less intense patches were also noted in
the cytoplasm of the cells (Fig. 1B). EBV-infected ST cells of nuclei positive for Zta. It is seen that treatment with
MAb OKB-7 at 12 mg/ml concentration resulted in 30%stained positively for VCA first on Day 4 when the reactiv-
ity of anti-VCA MAb was predominantly in the nuclei al- inhibition of EBV infection, but the degree of inhibition
could not be elevated up to 100% by further increase inthough some staining was also seen in the cytoplasm of
the cells (Fig. 1C). The cytoplasmic staining became the concentration of the antibody. Inhibitory effect of MAb
72A1, which can block the binding of EBV to B lympho-more intensive by Day 7 postinfection. The proportion of
VCA-positive cells ranged between 54 and 76% for the cytes, was similar to that of MAb OKB-7. In contrast to
MAb OKB-7, pretreatment of ST cells with MAb HB-5aindividual virus strains. The highest positivity was found
in AG 876 virus-infected cells, whereas the lowest posi- at concentration of 15 mg/ml or higher resulted in 68%
inhibition of virus infection. When mixtures of MAbs OKB-tivity was observed in Jijoye virus-infected cells. IFA us-
ing MAb against EBNA-2 gave consistently negative re- 7 and HB-5a were applied to the cells, complete inhibi-
tion of EBV infection was observed at a concentration ofsults independently of the EBV strains tested. All mock-
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FIG. 1. Indirect immunofluorescence staining of ST cells infected with AG 876 strain of EBV. (A) Zta at 24 hr after infection; (B) EA-D at 36 hr
after infection; (C) VCA at Day 4 after infection. Original magnification, 2001.
15 mg/ml. Similarly, infection of ST cells with EBV was HTLV-I replication could also be induced by preinfec-
totally blocked by purified gp350/220 in 15 mg/ml or tion of ST cells with AG 876 virus. However, this phenom-
higher concentrations. Blocking experiments performed enon proved to be time interval dependent. Only superna-
with other EBV strains gave essentially the same results tants from ST cells infected with HTLV-I within 12 days
(data not shown). after EBV infection were found to contain RT activity. In
contrast, superinfection of HTLV-I-infected cultures by
Virus replication in dually infected ST cultures EBV resulted in HTLV-I replication independently of the
time of coinfection. Interestingly, EBV replication was notNo stimulatory or inhibitory interactions were found
influenced by the time of coinfection (data not shown).between EBV and HIV-1 independently of the time of
Double infection experiments conducted with other EBVcoinfection (data not shown).
strains gave comparable results (data not shown).Simultaneous infection of ST cells with EBV and HTLV-
To investigate if HTLV-I assembly occurred, cell-freeI converted HTLV-I infection from a nonpermissive to a
supernatants from ST cultures coinfected simultaneouslypermissive one. Results of experiments performed with
with AG 876 strain of EBV and HTLV-I were tested forAG 876 strain of EBV and HTLV-I are shown in Fig. 5.
syncytium-inducing activity and infectivity in HOS cellsReverse transcriptase activity was detectable first on Day
as an indicator cell line. Syncytium formation and HTLV-9 after coinfection and reached a maximum value of 3.8
I production were scored on Day 21 after infection of1 105 cpm/ml of supernatant on Day 12. Then HTLV-I
HOS cells. Results summarized in Table 1 showed thatrelease by coinfected ST cells gradually decreased, and
RT activity in supernatants of coinfected cell cultures wasno detectable RT activity was found after 18 days post-
indicative of infectious HTLV-I.coinfection in the cultures. Simultaneous infection of ST
Expression of Tax protein in dually infected cells wascultures with EBV and HTLV-I did not alter the replication
observed first at 36 hr postcoinfection (Fig. 6), suggestingof EBV. It is noteworthy that heat inactivation of EBV (1
an inducing effect of EBV on HTLV-I in a very early stephr, 567) resulted in total abrogation of its inducing effect
on HTLV-I replication (data not shown). of HTLV-I replication.
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FIG. 4. Inhibition of EBV (AG 876 strain) infectivity by receptor block-
ade or by preincubation of virus with a gp350/220-specific monoclonal
antibody. Symbols: (n) MAb OKB-7; (,) MAb HB-5a; (m) MAbs OKB-7
plus HB-5a; (s) MAb 72A1; (h) gp350/220. Each value represents the
mean of three separate experiments. Standard deviations were within
14% of mean values.
FIG. 2. Western blot analysis of different cell extracts after serial
incubation and staining procedures as described in the text (POD and Effects of single and double infections with EBV and
AP conjugates with specific color substrates). Incubation 1, anti-Zta HTLV-I on cytokine synthesis
MAb (AP, red); incubation 2, anti-EA-D MAb (POD, brown). Lanes: 1,
Ramos cells; 2, Raji cells; 3, AG 876 cells induced with TPA and incu- To investigate the effects of EBV and HTLV-I on cyto-
bated for 3 days; 4, AG 876 virus-infected ST cells harvested on Day kine production, ST cells were infected in parallel with
4 postinfection; 5, mock-infected ST cells.
each virus or both of them. In some cases, before their
use for stimulation, viruses were inactivated by heat (1
Two-color IFA with mouse MAb to EBV VCA and goat hr, 567). The results obtained with various EBV strains
polyclonal antiserum against HTLV-I p24 showed the were essentially the same. No IFN-a, IFN-b, IL-1a, IL-
presence of both viruses in the same cells of ST cultures 1b, TNF-a, TGF-b2, TGF-b3, and GM-CSF activities were
coinfected simultaneously with AG 876 strain of EBV and found in supernatant fluids either before or after infection
HTLV-I (Fig. 7). The percentage of double-positive cells with EBV, HTLV-I, or both viruses. For the sake of simplic-
was above 50%. Coinfections performed with other ity, only cytokine releases from ST cells induced with the
strains of EBV and HTLV-I led to the same observation.
These findings demonstrated that individual ST cells
could serve as simultaneous targets for replication of
both viruses.
FIG. 5. Replication of EBV (AG 876 strain) and HTLV-I in singly and
dually infected ST cells. Coinfections with EBV and HTLV-I were per-
formed simultaneously. Symbols: (s) EBV release from cells infected
with EBV alone; (l) EBV release from cells coinfected with EBV and
HTLV-I; (n) HTLV-I release from cells infected with HTLV-I alone; (m)FIG. 3. Replication of various EBV strains in ST cells. Symbols: (s)
Akata; (n) Jijoye; (l) AG 876; (m) B95-8; (h) P3HR-1. Values shown HTLV-I release from cells coinfected with HTLV-I and EBV. The data
are the mean values obtained from three independent experiments.are representative of three separate experiments. Standard deviations
were not more than 17% for each time point. Standard deviations were not more than 19% for each time point.
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TABLE 1 reaching a maximal level of 970 pg/ml. Then there was
a gradual decrease in TNF-b activity of supernatants,Syncytium-Forming Activity and Replication of HTLV-I
and no TNF-b production was found after Day 6. HeatProduced by Dually Infected Syncytiotrophoblastsa
inactivation of either virus led to complete loss of TNF-
Titer of HTLV-I in HOS cells b production (data not shown).
as measured by Neither EBV nor HTLV-I was able to induce TGF-b1
production in singly infected ST cells (Fig. 11). However,RT activity of sample Syncytium formation RT activity
coinfection of the cells with EBV and HTLV-I resulted in(cpm/ml) (SFU/106 cells)b,c (cpm/ml)b,d
TGF-b1 production. The release of TGF-b1 from dually
6.2 1 104 3.7 { 0.4 1 102 7.1 { 0.5 1 104 infected cells started on Day 2, and the amounts of TGF-
3.8 1 105 2.4 { 0.2 1 103 4.3 { 0.3 1 105 b1 in supernatants were further increased by Day 4.
1.3 1 105 8.5 { 0.6 1 102 1.1 { 0.2 1 105
The peak level of TGF-b1 was 1650 pg/ml. After Day 44.7 1 104 3.1 { 0.3 1 102 4.9 1 0.6 1 104
postinfection, the TGF-b1 production gradually de-
a HOS cells cultured in a 12-well microtiter plate were infected with creased, and no TGF-b1 activity was found in the super-
1 ml of serial dilutions of samples for 2 hr at 377. The cells were natants on Day 7. Inactivation of EBV or HTLV-I resulted
passaged twice a week. Supernatants from uninfected syncytiotropho- in total abrogation of TGF-b1 production (data not
blast cultures were used as controls. Syncytium formation and RT activ-
shown).ity were scored on Day 21 after infection of HOS cells.
b Each value represents the average ({ standard deviations) from
Effects of antibodies to EBV-encoded proteins andthree independent experiments.
c Values are calculated for HOS cell cultures infected with undiluted virus-induced cytokines on HTLV-I replication in
supernatants. dually infected cells
d Values are given for HOS cell cultures infected with undiluted su-
pernatants. On the basis of the results of the foregoing experi-
ments, we postulated that both EBV-encoded proteins
and virus-induced cytokine production may be mediators
AG 876 strain of EBV alone or in combination with HTLV- of EBV-induced HTLV-I replication. To address this ques-
I are shown in Figs. 8–11. tion, monospecific antibodies were used as a means of
Uninfected ST cells constitutively released low levels blocking viral proteins and cytokine activities. Antibodies
(40 pg/ml) of IL-2 into the medium (Fig. 8). Live EBV to EBV Zta, EA-D, and VCA were chemically modified to
was found to enhance IL-2 production and maximal IL- increase their cellular penetration.
2 secretion (320 pg/ml) was observed at Day 5 after In order to reveal if anti-Zta MAb and anti-EA-D MAb
infection. Inactivated EBV was unable to induce IL-2 pro- can block the function of the appropriate EBV-encoded
duction (data not shown). In contrast to EBV, HTLV-I proteins (Holley-Guthrie et al., 1990; Li et al., 1987), we
alone had no IL-2-inducing potential. However, coinfec- first studied the ability of anti-Zta and anti-EA-D antibod-
tion of ST cells with both viruses further increased the ies to inhibit the expression of EA-D and VCA, respec-
rate of IL-2 production induced by EBV alone. The use tively. Treatment of EBV-infected ST cells with serial dilu-
of heat-inactivated HTLV-I resulted in the abrogation of tions of MAbs was started 24 hr before exposure to the
the HTLV-I effect on EBV-induced IL-2 production. virus. The medium was changed daily, and fresh antibod-
As shown in Fig. 9, live EBV induced IL-6 production ies were added till Day 10 after infection. The expression
in ST cell cultures. The IL-6 production started at Day 2
postinfection and reached a peak value of 1800 pg/ml at
Day 6. No IL-6 release was observed when an inactivated
preparation of EBV was tested (data not shown). In con-
trast to EBV, HTLV-I alone did not elicit any IL-6 produc-
tion. When ST cells were coinfected with EBV and HTLV-
I, an approximately 2.5-fold increase in IL-6 production
was detected compared with that in cells induced with
EBV alone. Live HTLV-I was required to enhance EBV-
induced IL-6 production, because heat-inactivated HTLV-
I was unable to cause a further increase in IL-6 release
(data not shown).
Supernatants of ST cell cultures infected with EBV or
HTLV-I alone did not contain any TNF-b activity, whereas
coinfection of cell cultures with both viruses resulted in
high levels of TNF-b release from dually infected cells FIG. 6. Detection of HTLV-I Tax protein in ST cells coinfected with
(Fig. 10). The production of TNF-b occurred at Day 2 EBV (AG 876 strain) and HTLV-I. Indirect immunofluorescence staining
was performed at 36 h after dual infection. Original magnification, 2001.after coinfection and increased significantly by Day 4,
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FIG. 7. Dually infected ST cells express both EBV (A) and HTLV-I (B) antigens. The chamber slide culture was fixed for immunofluorescence
staining on day 9 after simultaneous infection with AG 876 strain of EBV and HTLV-I. Cells were doubly stained with a mouse MAb to EBV VCA
and a goat polyclonal antiserum to HTLV-I p24, then counterstained with a TRITC-conjugated rabbit anti-mouse Ig serum and a FITC-conjugated
rabbit anti-goat Ig serum. The same field was photographed with bandpass filters for red or green epifluorescence. Controls: (C) EBV-infected ST
cells immunostained for VCA and visualized with TRITC-conjugated rabbit anti-mouse Ig serum; (D) HTLV-I-infected ST cells immunostained for
p24 and visualized with FITC-conjugated rabbit anti-goat Ig serum; (E) noninfected ST cells immunostained for EBV VCA and visualized with TRITC-
conjugated rabbit anti-mouse Ig serum; (F) noninfected ST cells immunostained for HTLV-I p24 and visualized with FITC-conjugated rabbit anti-
goat Ig serum. Original magnification, 1001.
of EA-D and VCA were determined by indirect cyto- manner. The expression of EA-D was completely inhib-
ited by 8 mg/ml anti-Zta. Similarly, expression of VCA wasplasmic IFA on Days 4 and 10 following EBV infection,
respectively. Results of experiments conducted with the totally blocked by anti-EA-D MAb in 6 mg/ml or higher
concentrations. In contrast, normal mouse immunoglobu-AG 876 strain of EBV are seen in Fig. 12. Anti-Zta MAb
blocked EA-D expression in a concentration-dependent lins did not exert any blocking effect on the expression
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FIG. 10. Kinetics of TNF-b production after exposure of ST cells to
EBV (AG 876), HTLV-I, or both viruses. Symbols: (s) cells infected with
EBV alone; (n) cells infected with HTLV-I alone; (j) cells infected withFIG. 8. Kinetics of IL-2 production after exposure of ST cells to EBV
(AG 876), HTLV-I or both viruses. Symbols: (h) uninfected cells; (s) EBV and HTLV-I simultaneously. Each value represents the mean from
three separate experiments. Standard deviations were within 14% ofcells infected with EBV alone; (n) cells infected with HTLV-I alone;
(j) cells infected with EBV and HTLV-I simultaneously. Each value mean values.
represents the mean from three separate experiments. Standard devia-
tions were within 15% of mean values.
pression of HTLV-I release from dually infected cells. In
contrast to anti-Zta, anti-EA-D, and anti-VCA MAbs up toof EA-D or VCA. Experiments carried out with other EBV
20 mg/ml had no inhibitory effect on EBV-induced HTLV-strains gave essentially the same results (data not
I replication. Blocking experiments conducted with othershown).
EBV strains gave essentially the same results (data notIn control experiments, uninfected ST cells were
shown).treated with chemically modified antibodies at various
No inhibitory effect of anti-IL-2, anti-IL-6, anti-TNF-b,concentrations up to 12 mg/ml for 6 days. There was no
or anti-TGF-b1 antibodies on HTLV-I replication was ob-difference in cell viability between antibody-treated and
served at concentrations of 10 mg/ml or higher (data notcontrol cultures as determined by the trypan blue dye
shown).exclusion test.
In the second series of studies, antibodies against
Activation of the latent HTLV-I genome by the BZLF1EBV-encoded proteins were applied to dually infected ST
transactivator of EBV in ST cellscultures at a concentration of 10 mg/ml.
Results of blocking experiments performed with the To more precisely reveal the effect of Zta on HTLV-I
AG 876 strain of EBV and HTLV-I are shown in Fig. 13. replication, we transfected ST cells with the pCMV-BZLF1
Treatment with anti-Zta MAb resulted in complete sup-
FIG. 9. Kinetics of IL-6 production after exposure of ST cells to EBV FIG. 11. Kinetics of TGF-b1 production after exposure of ST cells to
EBV (AG 876), HTLV-I, or both viruses. Symbols: (s) cells infected with(AG 876), HTLV-I or both viruses. Symbols: (s) cells infected with EBV
alone; (n) cells infected with HTLV-I alone; (j) cells infected with EBV EBV alone; (n) cells infected with HTLV-I alone; (j) cells infected with
EBV and HTLV-I simultaneously. Each value represents the mean fromand HTLV-I simultaneously. Each value represents the mean from three
separate experiments. Standard deviations were within 17% of mean three separate experiments. Standard deviations were within 16% of
mean values.values.
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FIG. 14. Induction of HTLV-I replication by the EBV BZLF1 gene
product in ST cells. Symbols: (s) BZLF1-transfected cells, uninfectedFIG. 12. Ability of monoclonal antibodies to Zta or EA-D to block EA-
with HTLV-I; (n) nontransfected cells infected with HTLV-I; (m) BZLF1-D or VCA expression in EBV (AG 876 strain)-infected ST cells. The rate
transfected cells infected with HTLV-I. The data are the mean valuesof inhibition of EA-D synthesis in cells treated with anti-Zta (s) or
obtained from three separate experiments. Standard deviations werenormal mouse immunoglobulins (h) and the rate of inhibition of VCA
within 20% of mean values.expression in cells treated with anti-EA-D (n) or normal mouse immu-
noglobulins (j) were evaluated by the decrease in the number of cells
positive for EA-D or VCA. Values are representative of three separate
experiments. Standard deviations were within 19% of mean values. Attempts to detect pseudotypes
Coinfection of ST cells with EBV and HTLV-I may result
plasmid. After allowing 36 hr for the expression of trans-
in formation of hybrid virions composed of the nucleocap-
fected DNA, the cell cultures were infected with HTLV-I.
sid of HTLV-I and the envelope of EBV, or vice versa.
The replication of HTLV-I was evaluated by monitoring
Progeny viruses from culture supernatant fluids har-
RT activity in the supernatant fluid of virus-infected cul-
vested on Day 12 following dual infection were tested
tures. As shown in Fig. 14, HTLV-I latency was disrupted
for the presence of pseudotypes by PCR. Control EBV
in ST cells by transfection of the EBV BZLF1 transactiva-
and HTLV-I pools and the experimental virus pool pro-
tor. In transfected cells RT activity could be detected first
duced in coinfected ST cells were added to Ramos andon Day 7 after HTLV-I infection and reached a maximum
HOS cell lines. On Day 3 after infection, genomic DNAlevel of 2 1 105 cpm/ml of supernatant on Day 11. Then
was extracted from the cells and then assessed for thethe HTLV-I release by transfected cells gradually de-
presence of viral-specific DNA by PCR. DNA samplescreased and was ceased by Day 18 postinfection.
from uninfected cells were used as negative controls.
Ramos cells were infectable only by EBV, whereas HOS
cells could be infected only by HTLV-I. No HTLV-I DNA
was detected in Ramos cells infected with supernatant
fluid of dually infected ST cell cultures. Similarly, we
could not demonstrate the presence of EBV DNA in HOS
cells infected with the experimental virus pool (data not
shown). These experiments provided no evidence for
pseudotype formation between EBV and HTLV-I.
DISCUSSION
Our findings show that EBV can productively infect
human ST cells. Two types of EBV were identified, EBV-
1 and EBV-2 represented by B95-8 or Akata and AG 876
or Jijoye, respectively (Zimber-Strobl et al., 1986). Our
FIG. 13. Effect of treatment with antibodies to EBV Zta, EA-D, and results did not reveal significant differences between
VCA on HTLV-I replication in dually infected ST cells. Cell cultures type 1 and type 2 EBV strains in their ability to replicate
were infected with EBV (AG 876) and HTLV-I simultaneously. Symbols: in ST cells. Moreover, the P3HR-1 EBV strain deleted for
(m) untreated cells; (n) cells treated with anti-Zta MAb; (s) cells treated
the EBNA-2 gene (King et al., 1982) could also replicatewith anti-EA-D MAb; (h) cells treated with anti-VCA MAb. Each value
efficiently in these cells. This finding is in line with therepresents the mean from three independent experiments. Standard
deviations were not more than 19% for each time point. observation that EBNA-2 is not required for productive
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virus replication in mucosal epithelial infections (Sixbey Although HTLV-I is able to enter ST cells, its replica-
tion is blocked in a very early step of the virus lifeet al., 1991).
The means by which EBV gains access to epithelial cycle. Results of the present study show that coinfec-
tion of these cells with EBV turns HTLV-I infection fromcells have been the subject of numerous studies. Re-
ceptor molecules similar but not identical to CR2 an abortive to a productive one. The blocking effect
of anti-Zta MAb on HTLV-I expression in dually in-(CD21) have been reported from epithelial cells of the
oropharynx (Sixbey et al., 1987). Our results demon- fected cells and the activation of the latent HTLV-I
genome by the transfected BZLF1 transactivator genestrate that human ST cells can express CD21, and that
CD21 can serve as a functional EBV receptor in these in ST cells indicate that EBV Zta protein plays a crucial
role in induction of the full replication cycle of HTLV-cells. However, the EBV receptor on ST cells appears
structurally different from the one found on B lympho- I. The precise mechanism of this effect is unknown;
however, the observation that Zta makes contact withcytes (Lowell et al., 1989) since EBV binding to ST
cells could not be completely blocked by MAbs OKB- the basic transcription factor TFIID and reduces the
dissociation rate of TFIID bound to the TATA element7 and 72A1. Our findings suggest that EBV can bind
to two different epitopes of CR2 on the surface of ST (Lieberman and Berk, 1991) suggests that the effect
is mediated via TATA-binding protein-associated fac-cells. Observation in support of this conclusion in-
cludes the different reactivity of epithelial cell plasma tors. Identification of cellular transcription factors in-
duced and/or activated by Zta will allow us to under-membranes with various CD21-specific MAbs (Birk-
enbach et al., 1992). stand the mechanism(s) of HTLV-I activation by EBV
in dually infected ST cells.The occurrence of congenital infection with EBV has
never been demonstrated conclusively and must be It is known that human trophoblast cells are capable
of producing IL-1, IL-2, TNF-a and -b, TGF-b, IFN-a andrare. Since EBV can replicate in ST cells, it is difficult
to comprehend this fact. Possibly, this is due to the -b, and GM-CSF (Mitchell et al., 1993). Of these, only
production of IL-2, IL-6, TNF-b, and TGF-b1 was inducedlack of B lymphocytes in the cell population underlin-
ing the placental ST layer (Enders, 1989). The basic in ST cells infected with EBV, HTLV-I, or both viruses.
None of these cytokines was causally related to induc-architecture of the villous stroma is constructed of
fixed connective tissue cells, free connective tissue tion of HTLV-I replication in dually infected cell cultures.
Since no IFN was released upon induction with HTLV-I,cells, and fetal vessels. Most free connective tissue
cells of human placental villi have been identified to an endogenous IFN response seems to have no role in
repression of HTLV-I replication in singly infected cells.be macrophages (Hofbauer cells). There are a few
cells, however, without macrophage character, among Similarly to HTLV-I, HIV-1 does not induce IFN production
in ST cells (To´th et al., 1995a).which are mast cells and lymphocytes. Mast cells and
lymphocytes are found mainly around the walls of the Transport of HTLV-I across the ST barrier would be
particularly efficient in delivery of the virus to its firstfetal blood vessels of villi. Two infants have been de-
scribed in whom there was evidence of infection with target cells, since placental macrophages lie immedi-
ately under the trophoblast layer (Goldstein et al., 1988).EBV at birth, and a congenital cytomegalovirus infec-
tion coexisted in both of them (Huang et al., 1978; The villous macrophages, termed Hofbauer cells, are
likely candidates for infection by the virus (Koralnik etJoncas et al., 1981). Thus, the possibility that congeni-
tal HCMV infection is necessary for intrauterine trans- al., 1992). Similar to other phagocytic cells, Hofbauer
cells are probably motile, and they occur in sufficientmission should be considered. It seems reasonable
to assume that HCMV could facilitate transplacental numbers potentially permit the transfer of HTLV-I to other
cells. Endothelial cells, lining placental blood vesselstransmission of EBV by pseudotype formation in ST
cells infected with both viruses. If hybrid virions con- may also become productively infected with the virus
(Hoxie et al., 1984).taining EBV nucleocapsids with HCMV envelopes
were to occur, they would provide EBV with the ability The finding that EBV had no effect on HIV-1 replication
in ST cells was a surprise, because both Zta and Rtato infect macrophages and fibroblasts in the underly-
ing connective tissue (Enders, 1989). To the best of have been shown to transactivate gene expression from
the HIV-1 LTR in HeLa and Jurkat cells cotransfected withour knowledge, such experimental studies have never
been performed. On the other hand, our data provided EBV BZLF1 and BRLF1 expression vectors, respectively
(Mallon et al., 1990; Quinlivan et al., 1990). However, inno evidence for pseudotype formation between HTLV-
I and EBV. Consequently, pseudotype formation be- addition to Zta and Rta, there are several additional cellu-
lar transcription factors which serve to mediate their ef-tween these viruses is unlikely to contribute to the
spread of EBV from mother to the fetus. Others have fects (Lieberman et al., 1990; Liu et al., 1996). Our results
suggest that the lack of the appropriate cellular transcrip-also failed to find evidence of pseudotype formation
between EBV and human retrovirus (van Kuyk and Mo- tion factors in ST cells totally abolishes Zta and Rta re-
sponsiveness of HIV-1 LTR in this system. Since bothsier, 1995).
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of transformation of lymphocytes by Epstein-Barr virus. Virology 76,EBV and HIV (Lu et al., 1989) make use of cellular tran-
152–163.scription factors for the control of viral gene expression,
Henderson, E. E., Yang, J. Y., Zhang, R. D., and Bealer, M. (1991). Alteredcompetition for the same cellular protein(s) may also de- HIV expression and EBV-induced transformation in coinfected PBLs
termine whether a viral infection is highly productive or and PBL subpopulations. Virology 182, 186–198.
not in dually infected cells. Henle, W., Henle, G., Zajac, B. A., Pearson, G., Waubke, R., and Scriba,
M. (1970). Differential reactivity of human serums with early antigensIn conclusion, the results from this study suggest that
induced by Epstein-Barr virus. Science 169, 188–190.in vivo double infection of ST cells with EBV and human
Hinuma, Y., Konn, M., Yamaguchi, J., Wudarski, D. J., Blakeslee, J. R.,retroviruses could contribute to the transplacental trans-
and Grace, J. T. (1967). Immunofluorescence and herpes type virus
mission of HTLV-I but not HIV-1. particles in the P3HR-1 Burkitt lymphoma cell line. J. Virol. 1, 1045–
1051.
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